IS8077A - Risahringa qínazólínafleiður sem miðlar gegn fjölgun - Google Patents

Risahringa qínazólínafleiður sem miðlar gegn fjölgun

Info

Publication number
IS8077A
IS8077A IS8077A IS8077A IS8077A IS 8077 A IS8077 A IS 8077A IS 8077 A IS8077 A IS 8077A IS 8077 A IS8077 A IS 8077A IS 8077 A IS8077 A IS 8077A
Authority
IS
Iceland
Prior art keywords
giant
quinazoline derivatives
mediate proliferation
mediate
proliferation
Prior art date
Application number
IS8077A
Other languages
English (en)
Other versions
IS3030B (is
Inventor
Jean Edgard Freyne Eddy
Pietro Suren Perera Timothy
Jan Rita Rombouts Frederik
Jacobus Johannes Antonius Buijnsters Peter
Willems Marc
Stanislas Marcella Diels Gaston
Constant Johan Embrechts Werner
Ten Holte Peter
Schultz-Fademrecht Carsten
Original Assignee
Janssen Pharmaceutica N.V.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=33493782&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=IS8077(A) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Janssen Pharmaceutica N.V. filed Critical Janssen Pharmaceutica N.V.
Publication of IS8077A publication Critical patent/IS8077A/is
Publication of IS3030B publication Critical patent/IS3030B/is

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/06—Peri-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/02—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C229/04—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated
    • C07C229/06—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton
    • C07C229/10—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings
    • C07C229/16—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being acyclic and saturated having only one amino and one carboxyl group bound to the carbon skeleton the nitrogen atom of the amino group being further bound to acyclic carbon atoms or to carbon atoms of rings other than six-membered aromatic rings to carbon atoms of hydrocarbon radicals substituted by amino or carboxyl groups, e.g. ethylenediamine-tetra-acetic acid, iminodiacetic acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C229/00—Compounds containing amino and carboxyl groups bound to the same carbon skeleton
    • C07C229/40—Compounds containing amino and carboxyl groups bound to the same carbon skeleton having amino groups bound to carbon atoms of at least one six-membered aromatic ring and carboxyl groups bound to acyclic carbon atoms of the same carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/88—Oxygen atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/93—Sulfur atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D239/00—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings
    • C07D239/70—Heterocyclic compounds containing 1,3-diazine or hydrogenated 1,3-diazine rings condensed with carbocyclic rings or ring systems
    • C07D239/72—Quinazolines; Hydrogenated quinazolines
    • C07D239/86—Quinazolines; Hydrogenated quinazolines with hetero atoms directly attached in position 4
    • C07D239/94—Nitrogen atoms

Landscapes

  • Organic Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Urology & Nephrology (AREA)
  • Vascular Medicine (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
IS8077A 2003-05-27 2005-10-14 Stórhringlaga kínasólín afleiður sem hemla á frumuskiptingu IS3030B (is)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
EP0305723 2003-05-27
EP0310266 2003-09-15
EP0351061 2003-12-18
PCT/EP2004/005621 WO2004105765A1 (en) 2003-05-27 2004-05-25 Macrocyclic quinazoline derivatives as antiproliferative agents

Publications (2)

Publication Number Publication Date
IS8077A true IS8077A (is) 2005-10-14
IS3030B IS3030B (is) 2021-06-15

Family

ID=33493782

Family Applications (1)

Application Number Title Priority Date Filing Date
IS8077A IS3030B (is) 2003-05-27 2005-10-14 Stórhringlaga kínasólín afleiður sem hemla á frumuskiptingu

Country Status (32)

Country Link
US (4) US7648975B2 (is)
EP (2) EP1633365B1 (is)
JP (1) JP4887151B2 (is)
KR (1) KR101143878B1 (is)
CN (1) CN102718775B (is)
AR (2) AR045687A1 (is)
AT (1) ATE544454T1 (is)
AU (1) AU2004243487B2 (is)
BR (1) BRPI0410714B8 (is)
CA (1) CA2525214C (is)
CL (1) CL2004001267A1 (is)
CO (1) CO5640038A2 (is)
CY (1) CY1113002T1 (is)
DK (1) DK1633365T3 (is)
EA (1) EA009064B1 (is)
ES (1) ES2381976T3 (is)
HK (1) HK1176350A1 (is)
HR (1) HRP20120351T1 (is)
IL (3) IL172154A0 (is)
IS (1) IS3030B (is)
JO (1) JO2785B1 (is)
MX (1) MXPA05012762A (is)
MY (1) MY148633A (is)
NO (1) NO334209B1 (is)
NZ (1) NZ544154A (is)
PA (1) PA8603801A1 (is)
PL (1) PL1633365T3 (is)
PT (1) PT1633365E (is)
SI (1) SI1633365T1 (is)
TW (3) TWI468397B (is)
UA (1) UA84010C2 (is)
WO (1) WO2004105765A1 (is)

Families Citing this family (51)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JO2785B1 (en) * 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives
WO2005048948A2 (en) * 2003-11-13 2005-06-02 Ambit Biosciences Corporation Urea derivatives as kinase modulators
CA2549728C (en) 2003-12-18 2015-07-21 Janssen Pharmaceutica N.V. 3-cyano-quinoline derivatives with antiproliferative activity
UA83881C2 (en) 2003-12-18 2008-08-26 Янссен Фармацевтика Н.В. Pyrido- and pyrimidopyrimidine derivatives as anti-proliferative agents
NI200700147A (es) 2004-12-08 2019-05-10 Janssen Pharmaceutica Nv Derivados de quinazolina inhibidores de cinasas dirigidos a multip
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
MY169441A (en) 2004-12-08 2019-04-11 Janssen Pharmaceutica Nv 2,4, (4,6) pyrimidine derivatives
PT1854789E (pt) 2005-02-23 2013-10-23 Shionogi & Co Derivado de quinazolina possuindo actividade inibidora de tirosina-cinase
GB0509227D0 (en) * 2005-05-05 2005-06-15 Chroma Therapeutics Ltd Intracellular enzyme inhibitors
ES2330789T3 (es) * 2005-06-30 2009-12-15 Janssen Pharmaceutica Nv Anilino-piridinotriazinas ciclicas como inhibidores de gsk-3.
MX2009000456A (es) * 2006-07-13 2009-01-27 Janssen Pharmaceutica Nv Derivados de quinazolina mtki.
JP2009242240A (ja) * 2006-08-04 2009-10-22 Mebiopharm Co Ltd 含ホウ素キナゾリン誘導体
US7547781B2 (en) 2006-09-11 2009-06-16 Curis, Inc. Quinazoline based EGFR inhibitors containing a zinc binding moiety
US7977347B2 (en) * 2006-09-11 2011-07-12 Curis, Inc. Quinazoline based EGFR inhibitors
CN101535279B (zh) 2006-09-11 2015-05-20 柯瑞斯公司 含锌结合基的喹唑啉基egfr抑制剂
EA200970420A1 (ru) * 2006-10-27 2009-12-30 Янссен Фармацевтика Нв Применение mtki 1 для лечения или предупреждения рака кости
WO2008049930A2 (en) * 2006-10-27 2008-05-02 Janssen Pharmaceutica Nv A method for profiling kinase inhibitors
AU2007310843A1 (en) * 2006-10-27 2008-05-02 Janssen Pharmaceutica Nv Macrocyclic quinazoline derivatives as VEGFR3 inhibitors
EA200970418A1 (ru) * 2006-10-27 2009-10-30 Янссен Фармацевтика Нв Применение мультитаргетного ингибитора киназ для лечения или предупреждения рака головного мозга
WO2008087736A1 (ja) * 2007-01-19 2008-07-24 Ube Industries, Ltd. アラルキルオキシ又はヘテロアラルキルオキシ基を有する芳香族アミンの製法
US8642067B2 (en) 2007-04-02 2014-02-04 Allergen, Inc. Methods and compositions for intraocular administration to treat ocular conditions
EP2185562B1 (en) 2007-07-27 2015-12-02 Janssen Pharmaceutica, N.V. Pyrrolopyrimidines useful for the treatment of proliferative diseases
US8119616B2 (en) 2007-09-10 2012-02-21 Curis, Inc. Formulation of quinazoline based EGFR inhibitors containing a zinc binding moiety
CL2008003384A1 (es) * 2007-11-14 2009-12-11 Enanta Pharm Inc Compuestos derivados de quinoxalina macrocíclica, inhibidores de serina proteasa; composicion farmaceutica que los comprende; y su uso en el tratamiento de la hepatitis c.
US8426430B2 (en) 2008-06-30 2013-04-23 Hutchison Medipharma Enterprises Limited Quinazoline derivatives
CN103965200B (zh) 2008-09-22 2016-06-08 阵列生物制药公司 作为trk激酶抑制剂的取代的咪唑并[1,2-b]哒嗪化合物
LT3372605T (lt) 2008-10-22 2022-02-10 Array Biopharma, Inc. Pakeistieji pirazolo[1,5-a]pirimidino junginiai, kaip trk kinazės inhibitoriai
WO2010085597A1 (en) * 2009-01-23 2010-07-29 Incyte Corporation Macrocyclic compounds and their use as kinase inhibitors
AR077468A1 (es) 2009-07-09 2011-08-31 Array Biopharma Inc Compuestos de pirazolo (1,5 -a) pirimidina sustituidos como inhibidores de trk- quinasa
TWI406853B (zh) * 2010-04-07 2013-09-01 Dev Center Biotechnology Ｅｇｆｒ與ｖｅｇｆｒ－２雙重抑制劑及其用途與製法
KR102132405B1 (ko) * 2010-05-20 2020-07-09 어레이 바이오파마 인크. Trk 키나제 저해제로서의 매크로시클릭 화합물
WO2013126015A1 (en) 2012-02-23 2013-08-29 N. V. Nutricia Composition comprising non- digestible oligosaccharides
DK2822953T5 (en) * 2012-03-06 2017-09-11 Pfizer Macrocyclic derivatives for the treatment of proliferative diseases
CN104513253A (zh) * 2013-10-01 2015-04-15 南京波尔泰药业科技有限公司 用于治疗增殖性疾病的大环化合物
JP6382997B2 (ja) * 2014-02-07 2018-08-29 エクセセーラ ファーマシューティカルズ インコーポレイテッド 治療用化合物および組成物
MA39822A (fr) 2014-04-03 2018-02-06 Janssen Pharmaceutica Nv Dérivés de pyrimidine bicycle
MA39823A (fr) * 2014-04-03 2018-01-09 Janssen Pharmaceutica Nv Dérivés de pyridine macrocyclique
RS64122B1 (sr) 2014-11-16 2023-05-31 Array Biopharma Inc Kristalni oblik (s)-n-(5-((r)-2-(2,5-difluorofenil)-pirolidin-1-il)-pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamid hidrogensulfata
CN108473435A (zh) 2015-10-05 2018-08-31 纽约市哥伦比亚大学理事会 自噬潮和磷脂酶d的活化剂以及包括tau的蛋白聚集体的清除和蛋白质病的治疗
BR112018008357A2 (pt) 2015-10-26 2018-11-27 Array Biopharma Inc mutações de ponto em câncer resistente a inibidor de trk e métodos relacionados às mesmas
EP3423113B1 (en) 2016-02-29 2020-09-02 Oncodesign S.A. Radiolabeled macrocyclic egfr inhibitor
US10045991B2 (en) 2016-04-04 2018-08-14 Loxo Oncology, Inc. Methods of treating pediatric cancers
AU2017246554B2 (en) 2016-04-04 2022-08-18 Loxo Oncology, Inc. Liquid formulations of (S)-N-(5-((R)-2-(2,5-difluorophenyl)-pyrrolidin-1-yl)-pyrazolo(1,5-a)pyrimidin-3-yl)-3-hydroxypyrrolidine-1-carboxamide
HRP20230704T1 (hr) 2016-05-18 2023-10-27 Loxo Oncology, Inc. Priprava (s)-n-(5-((r)-2-(2,5-difluorfenil)pirolidin-1-il)pirazolo[1,5-a]pirimidin-3-il)-3-hidroksipirolidin-1-karboksamida
JOP20190092A1 (ar) 2016-10-26 2019-04-25 Array Biopharma Inc عملية لتحضير مركبات بيرازولو[1، 5-a]بيريميدين وأملاح منها
JOP20190213A1 (ar) 2017-03-16 2019-09-16 Array Biopharma Inc مركبات حلقية ضخمة كمثبطات لكيناز ros1
WO2019113542A1 (en) * 2017-12-07 2019-06-13 Amplyx Pharmaceuticals, Inc. Heterocycle substituted pyridine derivative antifungal agents
CA3104653A1 (en) 2018-06-25 2020-01-02 Amplyx Pharmaceuticals, Inc. Pyridine derivatives substituted by heterocyclic ring and amino group
WO2021216440A1 (en) * 2020-04-20 2021-10-28 Tenova Pharmaceuticals Inc. Novel protein kinase inhibitors
WO2023114809A1 (en) 2021-12-16 2023-06-22 Kinnate Biopharma Inc. Inhibitors of met kinase
WO2024017258A1 (zh) * 2022-07-19 2024-01-25 百极弘烨(南通)医药科技有限公司 Egfr小分子抑制剂、含其的药物组合物及其用途

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BE558251A (is) 1956-06-11
DE2423536A1 (de) * 1974-05-15 1975-11-27 Bayer Ag 3-amino-phenylessigsaeure-derivate, verfahren zu ihrer herstellung sowie ihre verwendung als herbizide
US4066772A (en) * 1975-07-21 1978-01-03 Janssen Pharmaceutica N.V. 1,3-Dihydro-1-[3-(1-piperidinyl)propyl]-2H-benzimidazol-2-ones and related compounds
NZ181256A (en) 1975-07-21 1978-04-28 Janssen Pharmaceutica Nv 1-(w-benzazol-11-ylalkyl)-piperidine derivatives and pharmaceutical compositions containing certain of these derivatives
US4126687A (en) 1976-05-17 1978-11-21 Janssen Pharmaceutica N.V. Antiemetic, 1-(benzimidazolyl-alkyl)-piperidine derivatives
US5721237A (en) 1991-05-10 1998-02-24 Rhone-Poulenc Rorer Pharmaceuticals Inc. Protein tyrosine kinase aryl and heteroaryl quinazoline compounds having selective inhibition of HER-2 autophosphorylation properties
GB9510757D0 (en) * 1994-09-19 1995-07-19 Wellcome Found Therapeuticaly active compounds
GB9508538D0 (en) 1995-04-27 1995-06-14 Zeneca Ltd Quinazoline derivatives
RO121900B1 (ro) * 1996-04-12 2008-07-30 Warner-Lambert Company Compuşi inhibitori, ireversibili, ai tirozin kinazelor, compoziţie farmaceutică care îi conţine şi utilizarea acestora
GB9718972D0 (en) * 1996-09-25 1997-11-12 Zeneca Ltd Chemical compounds
CN1158266C (zh) 1998-10-01 2004-07-21 阿斯特拉曾尼卡有限公司 化合物
FR2809400B1 (fr) * 2000-05-25 2004-04-09 Inst Francais Du Petrole Materiaux comportant des groupements organiques contenant du soufre et du phosphore lie par l'intermediaire d'atomes d'oxygenes a un oxyde mineral
JO2785B1 (en) * 2003-05-27 2014-03-15 شركة جانسين فارماسوتيكا ان. في Quinazoline derivatives
JO3088B1 (ar) * 2004-12-08 2017-03-15 Janssen Pharmaceutica Nv مشتقات كوينازولين كبيرة الحلقات و استعمالها بصفتها موانع كينيز متعددة الاهداف
GB2446974B (en) * 2006-04-13 2009-01-14 Siemens Magnet Technology Ltd A solenoidal magnet structure

Also Published As

Publication number Publication date
TWI468372B (zh) 2015-01-11
BRPI0410714B1 (pt) 2019-09-24
BRPI0410714B8 (pt) 2021-05-25
US9273013B2 (en) 2016-03-01
AR092137A2 (es) 2015-03-25
MXPA05012762A (es) 2006-02-13
NO334209B1 (no) 2014-01-13
CL2004001267A1 (es) 2005-04-22
PL1633365T3 (pl) 2012-07-31
TW201245160A (en) 2012-11-16
CA2525214A1 (en) 2004-12-09
IL172154A0 (en) 2006-04-10
CO5640038A2 (es) 2006-05-31
CN102718775A (zh) 2012-10-10
IL233045A0 (en) 2014-07-31
US20130178624A1 (en) 2013-07-11
TWI379835B (en) 2012-12-21
TW200510431A (en) 2005-03-16
US8394786B2 (en) 2013-03-12
AU2004243487A1 (en) 2004-12-09
PA8603801A1 (es) 2004-12-16
TWI468397B (zh) 2015-01-11
ES2381976T3 (es) 2012-06-04
WO2004105765A1 (en) 2004-12-09
JO2785B1 (en) 2014-03-15
SI1633365T1 (sl) 2012-06-29
PT1633365E (pt) 2012-05-07
AR045687A1 (es) 2005-11-09
US7648975B2 (en) 2010-01-19
DK1633365T3 (da) 2012-05-14
IL233045B (en) 2018-07-31
IL233046A0 (en) 2014-07-31
KR101143878B1 (ko) 2012-05-24
EP1633365A1 (en) 2006-03-15
US20060247237A1 (en) 2006-11-02
UA84010C2 (en) 2008-09-10
ATE544454T1 (de) 2012-02-15
US20160207938A1 (en) 2016-07-21
HK1176350A1 (zh) 2013-07-26
BRPI0410714A (pt) 2006-06-13
NZ544154A (en) 2009-01-31
NO20056196L (no) 2005-12-28
HRP20120351T1 (hr) 2012-05-31
CN102718775B (zh) 2016-02-17
EA009064B1 (ru) 2007-10-26
JP4887151B2 (ja) 2012-02-29
EP1633365B1 (en) 2012-02-08
TW201245111A (en) 2012-11-16
EP2305687A1 (en) 2011-04-06
EA200501866A1 (ru) 2006-06-30
JP2007504276A (ja) 2007-03-01
IS3030B (is) 2021-06-15
CA2525214C (en) 2012-11-27
MY148633A (en) 2013-05-15
CY1113002T1 (el) 2016-04-13
AU2004243487B2 (en) 2009-12-03
KR20060014415A (ko) 2006-02-15
US20100105668A1 (en) 2010-04-29

Similar Documents

Publication Publication Date Title
IS8077A (is) Risahringa qínazólínafleiður sem miðlar gegn fjölgun
IS7884A (is) Díasepínóindól afleiður sem kínasa hindrar
ATE413389T1 (de) Chinazolinderivate
DE602004022180D1 (de) Chinazolinderivate
DE602004004553D1 (de) Chinazolinderivate
GB0322409D0 (en) Quinazoline derivatives
IL174534A0 (en) Quinazoline derivatives
IL182094A0 (en) Quinazoline derivatives
IS8238A (is) Pýrrólótvíhýdróísókínólín sem PDE10 tálmar
GB0321648D0 (en) Quinazoline derivatives
IL175421A0 (en) Quinazoline derivatives
IL174390A0 (en) Quinazoline derivatives
GB0330002D0 (en) Quinazoline derivatives
ATE433032T1 (de) Verriegelungsanordnung
GB0504018D0 (en) Quinazoline derivatives
ZA200603039B (en) Quinazoline derivatives
DE502004003715D1 (de) Selbstsperrender gurtaufroller
GB0321620D0 (en) Quinazoline derivatives
GB0406160D0 (en) Quinazoline derivatives
GB0406163D0 (en) Quinazoline derivatives
GB0426653D0 (en) Quinazoline derivatives
GB0506657D0 (en) Quinazoline derivatives
GB0524001D0 (en) Quinazoline derivatives
GB0501614D0 (en) Quinazoline derivatives
GB0322460D0 (en) Quinazoline derivatives